Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMM01 in refractory or relapsed lymphoma
ChiCTR1900024904Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of timdarpacept in lymphoma, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoints: Dose-limiting toxicity, Intolerable dose and 1 more. Started Aug 2019; status: recruiting.
02
Drugs
timdarpacept
03
Conditions
lymphoma
Beyond the preview
Go deeper on ChiCTR1900024904.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024904.